To test whether HCC onset and progression are sensitive to pharmacological targeting of plectin, we monitored Myc;sgTp53-driven tumor development in Plecfl/fl, PlecΔAlb, and PST-treated Plecfl/fl male mice using MRI (Figure 7A). This evidence concerns the gene PLEC and neoplasm.